189 related articles for article (PubMed ID: 37493109)
1. USF1-mediated ALKBH5 stabilizes FLII mRNA in an m6A-YTHDF2-dependent manner to repress glycolytic activity in prostate adenocarcinoma.
Fu D; Si Q; Yu C; Han Z; Zang L
Mol Carcinog; 2023 Nov; 62(11):1700-1716. PubMed ID: 37493109
[TBL] [Abstract][Full Text] [Related]
2. RNA demethylase ALKBH5 prevents pancreatic cancer progression by posttranscriptional activation of PER1 in an m6A-YTHDF2-dependent manner.
Guo X; Li K; Jiang W; Hu Y; Xiao W; Huang Y; Feng Y; Pan Q; Wan R
Mol Cancer; 2020 May; 19(1):91. PubMed ID: 32429928
[TBL] [Abstract][Full Text] [Related]
3. ALKBH5 regulates STAT3 activity to affect the proliferation and tumorigenicity of osteosarcoma via an m6A-YTHDF2-dependent manner.
Yang Z; Cai Z; Yang C; Luo Z; Bao X
EBioMedicine; 2022 Jun; 80():104019. PubMed ID: 35490460
[TBL] [Abstract][Full Text] [Related]
4. RNA demethylase ALKBH5 promotes colorectal cancer progression by posttranscriptional activation of RAB5A in an m6A-YTHDF2-dependent manner.
Shen D; Lin J; Xie Y; Zhuang Z; Xu G; Peng S; Tang G; Bai L; Zhu M; Zhang Y; Huang Z; Wang P; Liu X; Huang M; Luo Y; Wang X; Yu H
Clin Transl Med; 2023 May; 13(5):e1279. PubMed ID: 37203239
[TBL] [Abstract][Full Text] [Related]
5. ALKBH5 activates FAK signaling through m6A demethylation in
Sun R; Yuan L; Jiang Y; Wan Y; Ma X; Yang J; Sun G; Zhou S; Wang H; Qiu J; Zhang L; Cheng W
Theranostics; 2023; 13(2):833-848. PubMed ID: 36632222
[No Abstract] [Full Text] [Related]
6. Decreased
Luo Q; Gao Y; Zhang L; Rao J; Guo Y; Huang Z; Li J
Biomed Res Int; 2020; 2020():5735279. PubMed ID: 32884942
[TBL] [Abstract][Full Text] [Related]
7. ALKBH5-Mediated m6A Demethylation of GLUT4 mRNA Promotes Glycolysis and Resistance to HER2-Targeted Therapy in Breast Cancer.
Liu H; Lyu H; Jiang G; Chen D; Ruan S; Liu S; Zhou L; Yang M; Zeng S; He Z; Wang H; Li H; Zheng G; Liu B
Cancer Res; 2022 Nov; 82(21):3974-3986. PubMed ID: 36069931
[TBL] [Abstract][Full Text] [Related]
8. The m6A demethylase ALKBH5 promotes tumor progression by inhibiting RIG-I expression and interferon alpha production through the IKKε/TBK1/IRF3 pathway in head and neck squamous cell carcinoma.
Jin S; Li M; Chang H; Wang R; Zhang Z; Zhang J; He Y; Ma H
Mol Cancer; 2022 Apr; 21(1):97. PubMed ID: 35395767
[TBL] [Abstract][Full Text] [Related]
9. ALKBH5 inhibits the SIRT3/ACC1 axis to regulate fatty acid metabolism via an m6A-IGF2BP1-dependent manner in cervical squamous cell carcinoma.
Zhen L; Pan W
Clin Exp Pharmacol Physiol; 2023 May; 50(5):380-392. PubMed ID: 36705046
[TBL] [Abstract][Full Text] [Related]
10. HPV E7-drived ALKBH5 promotes cervical cancer progression by modulating m6A modification of PAK5.
Huo FC; Zhu ZM; Du WQ; Pan YJ; Jiang X; Kang MJ; Liu BW; Mou J; Pei DS
Pharmacol Res; 2023 Sep; 195():106863. PubMed ID: 37480971
[TBL] [Abstract][Full Text] [Related]
11. ALKBH5/YTHDF2-mediated m6A modification of circAFF2 enhances radiosensitivity of colorectal cancer by inhibiting Cullin neddylation.
Shao Y; Liu Z; Song X; Sun R; Zhou Y; Zhang D; Sun H; Huang J; Wu C; Gu W; Zheng X; Jiang J
Clin Transl Med; 2023 Jul; 13(7):e1318. PubMed ID: 37381158
[TBL] [Abstract][Full Text] [Related]
12. LINC00659 cooperated with ALKBH5 to accelerate gastric cancer progression by stabilising JAK1 mRNA in an m
Fang Y; Wu X; Gu Y; Shi R; Yu T; Pan Y; Zhang J; Jing X; Ma P; Shu Y
Clin Transl Med; 2023 Mar; 13(3):e1205. PubMed ID: 36864711
[TBL] [Abstract][Full Text] [Related]
13. ALKBH5-mediated m6A modification of lncRNA KCNQ1OT1 triggers the development of LSCC via upregulation of HOXA9.
Li Y; Yan B; Wang X; Li Q; Kan X; Wang J; Sun Y; Wang P; Tian L; Liu M
J Cell Mol Med; 2022 Jan; 26(2):385-398. PubMed ID: 34850551
[TBL] [Abstract][Full Text] [Related]
14. m6A hypomethylation of DNMT3B regulated by ALKBH5 promotes intervertebral disc degeneration via E4F1 deficiency.
Li G; Luo R; Zhang W; He S; Wang B; Liang H; Song Y; Ke W; Shi Y; Feng X; Zhao K; Wu X; Zhang Y; Wang K; Yang C
Clin Transl Med; 2022 Mar; 12(3):e765. PubMed ID: 35340126
[TBL] [Abstract][Full Text] [Related]
15. Loss of m6A demethylase ALKBH5 promotes post-ischemic angiogenesis via post-transcriptional stabilization of WNT5A.
Zhao Y; Hu J; Sun X; Yang K; Yang L; Kong L; Zhang B; Li F; Li C; Shi B; Hu K; Sun A; Ge J
Clin Transl Med; 2021 May; 11(5):e402. PubMed ID: 34047466
[TBL] [Abstract][Full Text] [Related]
16. ALKBH5 Inhibited Cell Proliferation and Sensitized Bladder Cancer Cells to Cisplatin by m6A-CK2α-Mediated Glycolysis.
Yu H; Yang X; Tang J; Si S; Zhou Z; Lu J; Han J; Yuan B; Wu Q; Lu Q; Yang H
Mol Ther Nucleic Acids; 2021 Mar; 23():27-41. PubMed ID: 33376625
[TBL] [Abstract][Full Text] [Related]
17. Suppression of m6A mRNA modification by DNA hypermethylated ALKBH5 aggravates the oncological behavior of KRAS mutation/LKB1 loss lung cancer.
Zhang D; Ning J; Okon I; Zheng X; Satyanarayana G; Song P; Xu S; Zou MH
Cell Death Dis; 2021 May; 12(6):518. PubMed ID: 34016959
[TBL] [Abstract][Full Text] [Related]
18.
Zhao X; Zhao Z; Xie H; Gao W; Ye C
Discov Med; 2024 Jan; 36(180):61-70. PubMed ID: 38273746
[TBL] [Abstract][Full Text] [Related]
19. Demethylase ALKBH5 suppresses invasion of gastric cancer via PKMYT1 m6A modification.
Hu Y; Gong C; Li Z; Liu J; Chen Y; Huang Y; Luo Q; Wang S; Hou Y; Yang S; Xiao Y
Mol Cancer; 2022 Feb; 21(1):34. PubMed ID: 35114989
[TBL] [Abstract][Full Text] [Related]
20. Down-regulated FTO and ALKBH5 co-operatively activates FOXO signaling through m6A methylation modification in HK2 mRNA mediated by IGF2BP2 to enhance glycolysis in colorectal cancer.
Ye M; Chen J; Lu F; Zhao M; Wu S; Hu C; Yu P; Kan J; Bai J; Tian Y; Tang Q
Cell Biosci; 2023 Aug; 13(1):148. PubMed ID: 37580808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
